 Selecta Biosciences Inc NASDAQ: SELB and Ginkgo Bioworks Holdings Inc NYSE: DNA have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. The partnership will leverage Ginkgos cell programming platform and Selectas ImmTOR platform to create potentially transformative enzymatic therapies. 